Esophageal is the tube like structure that connects mouth to stomach and help to get foods and liquid. Esophageal cancer develop uncontrolled cancerous cells anywhere along the esophagus. Esophageal cancer consider as a sixth most common cause of cancer deaths around the globe. The disease is characterized by disordered and deregulated cellular and stromal explosion along with reduced cell death and growth factor deprivation, and such other factors. The two main sub-types of esophageal cancer are esophageal squamous-cell carcinoma which arises from the epithelial cells and esophageal adenocarcinoma which arises from the glandular cells. According to the American Cancer Society in 2017 the esophageal cancer rate in the United States was about 16,940 cases diagnosed resulting in 15,690 deaths. The disease is also 3 to 4 times more common among men than women.
Get Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/3280
The global esophageal cancer market is showing the steady growth; mainly owing to increase in patient population. Also, the chances of develop esophageal cancer increases with age and the occurrence of esophageal cancer are much low in children and young adults in comparison to people over 55 year. According to report published by Cancer Research UK, in 2014, it is estimated that around 8,919 incidence of esophageal cancer found in the United Kingdom. These rising number of esophageal cancer create an opportunity for the player to introduce innovative treatment option.
Considering all these factors the market for esophageal cancer is expected to reach $ 1000.1 million by the end of 2023, this market is projected to growing at a CAGR of ~ 8.7 % during 2017-2023.
Key players of Global Esophageal cancer Market:
- Amgen
- Eli Lilly and Company,
- Hoffmann-La Roche,
- Bristol-Myers Squibb Company,
- Boehringer Ingelheim GmbH,
- Bristol-Myers Squibb,
- GlaxoSmithKline Plc.,
- Novartis AG,
- Johnson & Johnson,
- Gilead Sciences,
- Merck & Co.
Segmentation:
The global esophageal cancer market is segmented on the basis of type. Based on the type, the market has been segmented as esophageal squamous-cell carcinoma, esophageal adenocarcinoma and others. Based on the phases, the market has been segmented as phase I, phases II and phases III. Based on the treatment, the market has been segmented as surgery, chemotherapy and radiotherapy and other.
Intended Audience
- Global Esophageal cancer solutions providers, manufacturers & suppliers
- Research and development (R&D) companies
- Market research and consulting service providers
- Academic institutes and universities
Regional Analysis
US accounts for the maximum market share due to favorable reimbursement scenario and greater expenditure on healthcare. Europe is the second largest market due to large disposable income and rising awareness. Asia pacific region will be the fastest region because of large unmet needs which will be led by China and India. The Middle East and Africa market will be led by the gulf nations particularly Saudi Arabia and UAE. The poor regions of Africa is expected to be a laggard due to poor economic and political conditions.
Browse Complete 110 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/esophageal-cancer-market-3280
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com